GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Clinical trial NCT00546624 · COMPLETED

Trial details

NCT number: NCT00546624
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Anxiety Disorder

Start date: 2002-11-01
Primary completion: 2003-02-01
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.